You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient demographics and comorbidities by severity of psoriasis

From: Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database

Baseline characteristics in year 2010 Total Moderate to severe Mild p value
(N = 56,406; 100%) (N = 13,698; 24.3%) (N = 42,708; 75.7%)
Age (years), mean (SD) 51.63 (14.59) 51.79 (13.95) 51.58 (14.79) <0.0001
Male, n (%) 28,208 (50.01) 6717 (49.04) 21,491 (50.32) 0.0089
Female (%) 28,198 (49.99) 6981 (50.96) 21,217 (49.68)
Region
 North East 10,485 (18.59) 2478 (18.09) 8007 (18.75) 0.3327
 North Central 16,528 (29.30) 3988 (29.11) 12,540 (29.36)
 South 20,633 (36.58) 5076 (37.06) 15,557 (36.43)
 West 8660 (15.35) 2129 (15.54) 6531 (15.29)
 Missing 100 (0.18) 27 (0.20) 73 (0.17)
 Charlson Comorbidity Index, mean (SD) 0.38 (0.93)    
Comorbidities, n (%) Total Moderate to severe Mild p value
(n = 56,406) (n = 13,698; 24.3%) (n = 42,708; 75.7%)
Psoriatic arthritis 5557 (9.85) 2901 (21.18) 2656 (6.22) <0.0001
Cardiovascular disease 9992 (17.71) 2390 (17.45) 7602 (17.80) 0.3476
Depression 4388 (7.78) 1161 (8.48) 3227 (7.56) 0.0005
Anxiety 3148 (5.58) 734 (5.36) 2414 (5.65) 0.1923
Diabetes 8031 (14.24) 2181 (15.92) 5850 (13.70) <0.0001
Hyperlipidemia 18,911 (33.53) 4572 (33.38) 14,339 (33.57) 0.6703
Hypertension 19,365 (34.33) 4775 (34.86) 14,590 (34.16) 0.1350
Obesity 2755 (4.88) 709 (5.18) 2046 (4.79) 0.0687
Cerebrovascular disease 2122 (3.76) 462 (3.37) 1660 (3.89) 0.0059
Peripheral vascular disease 2032 (3.60) 457 (3.34) 1575 (3.69) 0.0547
Any of the above comorbiditiesa 35,644 (63.19) 9294 (67.85) 26,350 (61.70) <0.0001
  1. aAny of the above comorbidities means if patients have any of the either comorbidities mentioned above. The percentages do not add up as they are not mutually exclusive